GPX4 and diabetes mellitus: These data reveal that MAP4K4 and SNO-Drp1 promote the development of cardiac microvascular dysfunction in diabetes and provide theoretical evidence that the MAP4K4-GPX4-Drp1 signaling pathway is a novel therapeutic target for DCM.